CTOs on the Move


 
Our name, Aptuit, is derived from the words aptitude and intuition, two natural attributes that define our unique approach to providing drug discovery, development and manufacturing support. The name communicates our aptitude for scientific knowledge as well as our intuitive understanding of the needs of the pharmaceutical and biotechnological community. We summon these attributes to clarify current challenges and anticipate those that are to come, always with the determination to find solutions.   Since Aptuit was founded in 2004, we have forged a robust expansion of our resources. We are living up to the promise of our name by the ongoing assembly ...
  • Number of Employees: 10K-50K
  • Annual Revenue: $500M-1 Billion
  • www.aptuit.com
  • 2 Greenwich Office Park
    Greenwich, CT USA 06831
  • Phone: 855.506.6360

Executives

Name Title Contact Details

Similar Companies

Sequella

Sequella is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

2nd Chance Treatment Center

Telehealth Available: Trusted Addiction Medicine serving the greater Phoenix, AZ area. Visit our website to book an appointment online: 2nd Chance Treatment Center

Wellgistics

Wellgistics is an NABP Accredited Drug Distributor licensed in all 50 states. We are maniacal about compliance and never carry gray market products, 100% direct

X4 Pharmaceuticals

X4 Pharmaceuticals (Nasdaq: XFOR) is developing novel therapeutics designed to improve immune cell trafficking to treat rare diseases, including primary immunodeficiencies and certain cancers. The company`s oral small molecule drug candidates antagonize the CXCR4 pathway, which plays a central role in immune surveillance. X4`s most advanced product candidate, mavorixafor (X4P-001), is in a global Phase 3 pivotal trial in patients with WHIM syndrome, a rare, inherited, primary immunodeficiency disease, and is currently also under investigation in combination with axitinib in the Phase 2a portion of an open-label Phase 1/2 clinical trial in clear cell renal cell carcinoma (ccRCC). X4 is also planning to commence clinical trials of mavorixafor in Severe Congenital Neutropenia (SCN) and Waldenström`s macroglobulinemia (WM) in 2019. The company was founded and is led by a team with extensive biopharmaceutical product development and commercialization expertise and is committed to advancing the development of innovative medicines on behalf of patients with limited treatment options. X4 is a global company that is headquartered in Cambridge, Massachusetts with research offices based in Vienna, Austria.

Amneal

Amneal (NYSE:AMRX) is building one of the most dynamic pharmaceutical companies in our industry. Today`s healthcare environment requires new ideas. While staying true to our reputation for quality, service and value in pharmaceuticals, we are challenging ourselves, our playbook and the status quo. We are uniting people, passion and products to deliver outcomes that meet important medical needs, make quality medicines more accessible and more affordable, and provide solutions for tomorrow`s health challenges. We are Amneal and “We make healthy possible.” Learn more about how we`re making a difference in generics, brands and biosimilars at Amneal.com.